Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.
IBB vs IJR: how they differ
IBB and IJR hold 2% of their weight in the same names, and IBB returned more over the year.
iShares Biotechnology ETF and iShares Core S&P Small-Cap ETF.
What they hold in common
By the books each fund has filed, IBB and IJR hold 2% of their money in the same securities at the same weight.
| Holding | IBB | IJR |
|---|---|---|
| Krystal Biotech, Inc. | 0.75% | 0.54% |
| Protagonist Therapeutics, Inc. | 0.58% | 0.41% |
| PTC Therapeutics, Inc. | 0.51% | 0.38% |
| Veracyte, Inc. | 0.36% | 0.26% |
| ACADIA Pharmaceuticals, Inc. | 0.33% | 0.18% |
| Arcus Biosciences, Inc. | 0.20% | 0.15% |
| Vericel Corp. | 0.17% | 0.13% |
| ADMA Biologics, Inc. | 0.15% | 0.11% |
| Sarepta Therapeutics, Inc. | 0.14% | 0.10% |
| Fortrea Holdings, Inc. | 0.13% | 0.09% |
| Vir Biotechnology, Inc. | 0.11% | 0.07% |
| Xencor, Inc. | 0.09% | 0.07% |
| Only in IBB | Only in IJR |
|---|---|
| Vertex Pharmaceuticals, Inc. 8.09% | FORMFACTOR INC 0.69% |
| Amgen, Inc. 7.84% | VIASAT INC 0.68% |
| Gilead Sciences, Inc. 6.85% | MOLINA HEALTHCARE INC 0.66% |
| Regeneron Pharmaceuticals, Inc. 4.91% | ARGAN INC 0.62% |
| Argenx SE 3.76% | BRIGHTSPRING HEALTH SERVICES INC 0.61% |
| Alnylam Pharmaceuticals, Inc. 3.12% | ELEMENT SOLUTIONS INC 0.61% |
| Natera, Inc. 2.89% | MAXLINEAR INC 0.60% |
| Revolution Medicines, Inc. 2.78% | ESCO TECHNOLOGIES INC 0.50% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Jun 30, 2026.
| IBB iShares Biotechnology ETF | IJR iShares Core S&P Small-Cap ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | iShares | iShares |
| What it is | Biotechnology | S&P SmallCap 600 |
| Total return, 1 year | +41.5% | +19.9% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | +24.0 pts | +2.4 pts |
| Expense ratio | 0.44% | 0.06% |
| Already in the S&P 500 | 35.6% | 0.0% |
| Holdings | 248 | 603 |
IBB in plain words
IBB is an index equity fund tracking the Biotechnology. Over the year to Sep 11, 2026 it returned +41.5% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.44% a year. By its holdings filed for Jun 30, 2026, 36% of the fund by weight is stocks the S&P 500 also holds, across 248 positions, with the top ten at 44.8%. It sat 6.5% below its high of Aug 19, 2026 on Sep 11, 2026.
IJR in plain words
IJR is an index equity fund tracking the S&P SmallCap 600. Over the year to Sep 11, 2026 it returned +19.9% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.06% a year. By its holdings filed for Jun 30, 2026, 0% of the fund by weight is stocks the S&P 500 also holds, across 603 positions, with the top ten at 6.0%. It sat 5.5% below its high of Aug 14, 2026 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, IBB or IJR?
- In the year to Sep 12, 2026, with distributions reinvested, IBB returned +41.5% and IJR returned +19.9%, so IBB returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, IBB or IJR?
- IBB charges 0.44% a year and IJR charges 0.06%, so IJR is cheaper. Fees come from each fund's prospectus.
- How much do IBB and IJR overlap with the S&P 500?
- By their latest filed holdings, 36% of IBB and 0% of IJR by weight is stocks the S&P 500 already holds. Between the two funds, 2% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, IBB against IJR, data as of Sep 12, 2026. https://etfiq.com/compare/any/IBB-IJR Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources